FI112477B - Klooripyrimidiinivälituotteita, niiden valmistus ja menetelmä 2-aminopuriinien valmistamiseksi - Google Patents

Klooripyrimidiinivälituotteita, niiden valmistus ja menetelmä 2-aminopuriinien valmistamiseksi Download PDF

Info

Publication number
FI112477B
FI112477B FI963070A FI963070A FI112477B FI 112477 B FI112477 B FI 112477B FI 963070 A FI963070 A FI 963070A FI 963070 A FI963070 A FI 963070A FI 112477 B FI112477 B FI 112477B
Authority
FI
Finland
Prior art keywords
formula
amino
compound
compounds
preparation
Prior art date
Application number
FI963070A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI963070A0 (fi
FI963070A (fi
Inventor
Susan Mary Daluge
Michael Tolar Martin
Michelle Joanne Ferry Fugett
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10749873&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI112477(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of FI963070A0 publication Critical patent/FI963070A0/fi
Publication of FI963070A publication Critical patent/FI963070A/fi
Application granted granted Critical
Publication of FI112477B publication Critical patent/FI112477B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Catalysts (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Indole Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI963070A 1994-02-04 1996-08-02 Klooripyrimidiinivälituotteita, niiden valmistus ja menetelmä 2-aminopuriinien valmistamiseksi FI112477B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9402161 1994-02-04
GB9402161A GB9402161D0 (en) 1994-02-04 1994-02-04 Chloropyrimidine intermediates
GB9500225 1995-02-03
PCT/GB1995/000225 WO1995021161A1 (en) 1994-02-04 1995-02-03 Chloropyrimide intermediates

Publications (3)

Publication Number Publication Date
FI963070A0 FI963070A0 (fi) 1996-08-02
FI963070A FI963070A (fi) 1996-08-02
FI112477B true FI112477B (fi) 2003-12-15

Family

ID=10749873

Family Applications (1)

Application Number Title Priority Date Filing Date
FI963070A FI112477B (fi) 1994-02-04 1996-08-02 Klooripyrimidiinivälituotteita, niiden valmistus ja menetelmä 2-aminopuriinien valmistamiseksi

Country Status (28)

Country Link
US (8) US6448403B1 (ja)
EP (1) EP0741710B1 (ja)
JP (1) JP3670012B2 (ja)
KR (1) KR100355983B1 (ja)
CN (2) CN1105109C (ja)
AT (1) ATE192742T1 (ja)
AU (1) AU690203B2 (ja)
BR (1) BR9506667A (ja)
DE (1) DE69516847T2 (ja)
DK (1) DK0741710T3 (ja)
ES (1) ES2148486T3 (ja)
FI (1) FI112477B (ja)
GB (1) GB9402161D0 (ja)
GR (1) GR3033850T3 (ja)
HK (1) HK1004087A1 (ja)
HU (1) HU223096B1 (ja)
IL (1) IL112539A (ja)
MX (1) MX9603091A (ja)
MY (1) MY113775A (ja)
NO (1) NO310819B1 (ja)
NZ (1) NZ278948A (ja)
PL (1) PL183885B1 (ja)
PT (1) PT741710E (ja)
RU (1) RU2140913C1 (ja)
SG (1) SG47918A1 (ja)
TW (1) TW390877B (ja)
WO (1) WO1995021161A1 (ja)
ZA (1) ZA95884B (ja)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9402161D0 (en) * 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
CA2145928C (en) * 1994-04-27 2007-10-09 Gerhard Stucky N-(2-amino-4,6-dichloropyrimidin-5-yl)formamide, and a process for its preparation
SK285228B6 (sk) 1997-05-13 2006-09-07 Lonza Ag Spôsob výroby racemického alebo opticky aktívnehoderivátu 4-(hydroxymetyl)-2-cyklopenténu a racemicky N-butyryl-1-amino-4- (hydroxymetyl)-2-cyklopentén
GB9721780D0 (en) * 1997-10-14 1997-12-10 Glaxo Group Ltd Process for the synthesis of chloropurine intermediates
AU2702899A (en) * 1997-10-24 1999-05-17 Glaxo Group Limited Process for preparing a chiral nucleoside analogue
JP2001522850A (ja) * 1997-11-12 2001-11-20 グラクソ グループ リミテッド キラルヌクレオシド類似体の製造法
SK284416B6 (sk) * 1997-11-27 2005-03-04 Lonza Ag Spôsob výroby derivátov aminoalkoholov
ATE228508T1 (de) * 1998-12-21 2002-12-15 Lonza Ag Verfahren zur herstellung von n-(amino-4,6- dihalogenpyrimidin)-formamiden
AU2002252179A1 (en) * 2001-03-01 2002-09-19 Conforma Therapeutics Corp. Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors
EP1440072A4 (en) * 2001-10-30 2005-02-02 Conforma Therapeutic Corp PURINE ANALOGS HAVING HSP90 INHIBITORY ACTIVITY
US20070129334A1 (en) * 2001-10-30 2007-06-07 Conforma Therapeutics Corporation Orally Active Purine-Based Inhibitors of Heat Shock Protein 90
US6780635B2 (en) 2001-12-27 2004-08-24 Council Of Scientific And Industrial Research Process for the preparation of optically active azabicyclo heptanone derivatives
KR100573859B1 (ko) * 2002-07-15 2006-04-25 경동제약 주식회사 9-[4-아세톡시-3-(아세톡시메틸)부트-1-일]-2-아미노푸린의제조방법
US7560231B2 (en) * 2002-12-20 2009-07-14 Roche Molecular Systems, Inc. Mannitol and glucitol derivatives
CA2522573A1 (en) * 2003-04-30 2004-11-18 Teva Pharmaceutical Industries Ltd. Process for the preparation of famciclovir
JPWO2004103979A1 (ja) * 2003-05-26 2006-07-20 住友化学株式会社 Ｎ−（２−アミノ−４，６−ジクロロピリミジン−５−イル）ホルムアミドの製造方法
KR100573860B1 (ko) * 2003-06-13 2006-04-25 경동제약 주식회사 2-아미노-9-(2-치환에틸)푸린을 이용한 9-[4-아세톡시-3-(아세톡시메틸)부트-1-일]-2-아미노푸린의 제조방법
US6930093B2 (en) * 2003-07-10 2005-08-16 Valeant Research & Development Use of ribofuranose derivatives against inflammatory bowel diseases
KR100573861B1 (ko) * 2003-07-18 2006-04-25 경동제약 주식회사 2-아미노-9-(2-할로게노에틸)푸린 및 그 중간체로서의 2-아미노-6,8-디클로로-9-(2-히드록시에틸)푸린의 제조방법
GB0320738D0 (en) * 2003-09-04 2003-10-08 Glaxo Group Ltd Novel process
EP1556383A1 (en) * 2003-09-04 2005-07-27 Teva Pharmaceutical Industries Ltd. Process for preparing famciclovir
US7148228B2 (en) * 2003-09-18 2006-12-12 Conforma Therapeutics Corporation Pyrazolopyrimidines and related analogs as HSP90-inhibitors
DE102004002055A1 (de) * 2004-01-15 2005-08-11 Degussa Ag Verfahren zur Herstellung von 2-Amino-4,6-dichlor-5-formamidopyrimidin
AP2007003921A0 (en) * 2004-08-16 2007-02-28 Atugen Ag Therapeutic uses of inhibitors of rtp801
KR20080004550A (ko) 2005-03-30 2008-01-09 콘포마 세러퓨틱스 코포레이션 Ｈｓｐ９０-억제제로서 알키닐 피롤로피리미딘 및 관련유사체
GB2426247A (en) 2005-05-20 2006-11-22 Arrow Int Ltd Methods of preparing purine derivatives such as famciclovir
WO2007035963A2 (en) * 2005-09-23 2007-03-29 Conforma Therapeutics Corporation Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors
EP1857458A1 (en) * 2006-05-05 2007-11-21 SOLMAG S.p.A. Process for the preparation of abacavir
CN100465174C (zh) * 2006-06-13 2009-03-04 中国科学院上海有机化学研究所 制备光学纯阿巴卡韦的方法
WO2008072074A1 (en) * 2006-12-11 2008-06-19 Aurobindo Pharma Limited An improved process for the preparation of purine derivative
EP1939196A1 (en) * 2006-12-21 2008-07-02 Esteve Quimica, S.A. Process for the preparation of abacavir
WO2008155613A1 (en) * 2007-06-21 2008-12-24 Aurobindo Pharma Ltd An improved process for preparing purine derivative
EP2085397A1 (en) 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
RS54123B1 (en) 2010-01-27 2015-12-31 Viiv Healthcare Company THERAPEUTIC COMBINATION CONTAINING DOLUTEGRAVIR, ABACAVIR AND LAMIVUDINE
CZ305457B6 (cs) * 2011-02-28 2015-09-30 Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití
WO2014133085A1 (ja) 2013-02-27 2014-09-04 国立大学法人京都大学 がんの予防または治療用医薬組成物
CN104672239A (zh) * 2013-11-26 2015-06-03 上海迪赛诺化学制药有限公司 一种采用一锅法制备阿巴卡韦式v中间体的工艺
CN109456329B (zh) * 2018-11-19 2021-03-09 迪嘉药业集团有限公司 一种泛昔洛韦的制备方法
CN113292507B (zh) * 2021-06-25 2022-07-19 潍坊奥通药业有限公司 一种2-氨基-6-氯鸟嘌呤及其中间体的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0141927B1 (en) 1983-08-18 1991-10-30 Beecham Group Plc Antiviral guanine derivatives
EP0182024B1 (en) 1984-09-20 1991-04-03 Beecham Group Plc Purine derivatives and their pharmaceutical use
US4965270A (en) 1987-05-30 1990-10-23 Beecham Group P.L.C. Purine derivatives
GB8724765D0 (en) 1987-10-22 1987-11-25 Beecham Group Plc Process
US4916224A (en) 1988-01-20 1990-04-10 Regents Of The University Of Minnesota Dideoxycarbocyclic nucleosides
US5631370A (en) 1988-01-20 1997-05-20 Regents Of The University Of Minnesota Optically-active isomers of dideoxycarbocyclic nucleosides
GB2243609B (en) * 1988-01-20 1992-03-11 Univ Minnesota Dideoxydidehydrocarbocyclic pyrimidines
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
GB8916698D0 (en) 1989-07-21 1989-09-06 Beecham Group Plc Novel process
GB8918827D0 (en) 1989-08-17 1989-09-27 Beecham Group Plc Novel compounds
MY104575A (en) 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
SK279618B6 (sk) 1992-01-22 1999-01-11 Lonza A.G. (Dir.:Basel) N-5-chránené 2,5-diamino-4,6-dichlórpyrimidíny a s
GB9402161D0 (en) * 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
CA2145928C (en) 1994-04-27 2007-10-09 Gerhard Stucky N-(2-amino-4,6-dichloropyrimidin-5-yl)formamide, and a process for its preparation

Also Published As

Publication number Publication date
US5917041A (en) 1999-06-29
EP0741710A1 (en) 1996-11-13
MY113775A (en) 2002-05-31
US6448403B1 (en) 2002-09-10
AU1543895A (en) 1995-08-21
HK1004087A1 (en) 1998-11-13
NO963239L (no) 1996-10-02
FI963070A0 (fi) 1996-08-02
HU9602114D0 (en) 1996-09-30
CN1139924A (zh) 1997-01-08
CN1105109C (zh) 2003-04-09
KR100355983B1 (ko) 2002-12-28
US6552193B1 (en) 2003-04-22
JPH09508412A (ja) 1997-08-26
NZ278948A (en) 1998-01-26
US6870053B2 (en) 2005-03-22
US6087501A (en) 2000-07-11
DE69516847D1 (de) 2000-06-15
US20020173649A1 (en) 2002-11-21
DE69516847T2 (de) 2000-10-26
JP3670012B2 (ja) 2005-07-13
SG47918A1 (en) 1998-04-17
BR9506667A (pt) 1997-09-16
WO1995021161A1 (en) 1995-08-10
AU690203B2 (en) 1998-04-23
ZA95884B (en) 1996-08-05
PL315713A1 (en) 1996-11-25
US5917042A (en) 1999-06-29
PL183885B1 (pl) 2002-07-31
US6555687B1 (en) 2003-04-29
GR3033850T3 (en) 2000-10-31
US20030187263A1 (en) 2003-10-02
ES2148486T3 (es) 2000-10-16
EP0741710B1 (en) 2000-05-10
CN1388123A (zh) 2003-01-01
GB9402161D0 (en) 1994-03-30
IL112539A0 (en) 1995-05-26
ATE192742T1 (de) 2000-05-15
NO963239D0 (no) 1996-08-02
PT741710E (pt) 2000-09-29
IL112539A (en) 2000-08-31
TW390877B (en) 2000-05-21
RU2140913C1 (ru) 1999-11-10
FI963070A (fi) 1996-08-02
MX9603091A (es) 1998-01-31
DK0741710T3 (da) 2000-08-14
NO310819B1 (no) 2001-09-03
HU223096B1 (hu) 2004-03-29
HUT75300A (en) 1997-05-28
CN1161343C (zh) 2004-08-11

Similar Documents

Publication Publication Date Title
FI112477B (fi) Klooripyrimidiinivälituotteita, niiden valmistus ja menetelmä 2-aminopuriinien valmistamiseksi
MXPA96003091A (en) Cloropirimid intermediaries
US4323570A (en) Substituted aminopyrimidines
AU645698B2 (en) 4-pyrimidinecarboxamide derivatives, their preparation and their application in therapy
EP0260491B1 (en) 9-deazaguanines
US5216161A (en) Process for preparing 2,5-diamino-4,6-dichloropyrimidine
PL150841B1 (en) Purine compounds.
CA1294960C (en) 7-deazaguanines as immunomodulators
CS242894B2 (en) Method of compounds production with a diazotized heterocyclic core
DK156722B (da) Analogifremgangsmaade til fremstilling af 2-piperazinopyrimidinderivater
KR100543845B1 (ko) 클로로푸린 중간체의 합성 방법
CA2182105C (en) Chloropyrimide intermediates
US3461131A (en) Process for preparing 2-substituted cycloheptimidazole derivatives
US6184382B1 (en) Process for preparing N6-substituted adenosine derivatives
JPH0417195B2 (ja)
IL129935A (en) Chloropyrimidine intermediates for preparing 2-aminopurine nucleoside analogues and their preparation
US4996319A (en) -2-Amino-4,6-dichloro-5-(2-cyanomethyl-2-amino-5(cyanomethyl)-4,6-dichloro pyrimidine
MXPA00003379A (en) Process for the synthesis of chloropurine intermediates
GB2161158A (en) Benzylpyrimidine synthesis and intermediates

Legal Events

Date Code Title Description
MA Patent expired